Regulation of fibroblast growth factor-23 in chronic kidney disease.
暂无分享,去创建一个
[1] B. Leder,et al. Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. , 2007, Bone.
[2] K. Okawa,et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.
[3] T. Yamashita,et al. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. , 2006, The Journal of clinical endocrinology and metabolism.
[4] Hang Lee,et al. Regulation of C‐Terminal and Intact FGF‐23 by Dietary Phosphate in Men and Women , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] M. Wolf,et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.
[6] S. Fukumoto,et al. Intravenous Calcitriol Therapy Increases Serum Concentrations of Fibroblast Growth Factor-23 in Dialysis Patients with Secondary Hyperparathyroidism , 2005, Nephron Clinical Practice.
[7] S. Mooney,et al. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. , 2005, The Journal of clinical endocrinology and metabolism.
[8] T. Shigematsu,et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. , 2005, Kidney international.
[9] R. Rizzoli,et al. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. , 2005, The Journal of clinical endocrinology and metabolism.
[10] P. Orlik,et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. , 2005, Human molecular genetics.
[11] T. Shigematsu,et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] M. Inaba,et al. FGF-23 in patients with end-stage renal disease on hemodialysis. , 2004, Kidney international.
[13] H. Jüppner,et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. , 2003, Kidney international.
[14] L. Quarles,et al. Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEX* , 2003, Journal of Biological Chemistry.
[15] S. Fukumoto,et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.
[16] L. Quarles,et al. Serum FGF23 Levels in Normal and Disordered Phosphorus Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] Y. Takeuchi,et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. , 2002, The Journal of clinical endocrinology and metabolism.
[18] S. Takeda,et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[19] T. Meitinger,et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 , 2000, Nature Genetics.